Goldman Sachs analyst Terence Flynn upgraded Biogen following the company's Q2 earnings report and raised his price target for the shares to $338 from $288. The drugmaker closed yesterday down $1.74 to $282.96. Biogen's balance sheet is under-levered, which provides flexibility, while Aducanumab provides Alzheimer's optionality, Flynn tells investors in a research note.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here